Pulmonx Analyst Ratings
Pulmonx Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/05/2023 | 76.13% | Craig-Hallum | → $18 | Initiates Coverage On | → Buy |
| 08/03/2023 | 66.34% | Piper Sandler | $15 → $17 | Maintains | Overweight |
| 07/11/2023 | 56.56% | Citigroup | $14 → $16 | Maintains | Buy |
| 05/03/2023 | 36.99% | Citigroup | $13 → $14 | Maintains | Buy |
| 05/03/2023 | 46.77% | Piper Sandler | $13 → $15 | Maintains | Overweight |
| 05/03/2023 | 36.99% | Morgan Stanley | $11 → $14 | Maintains | Equal-Weight |
| 04/03/2023 | 27.2% | Citigroup | $12 → $13 | Maintains | Buy |
| 02/27/2023 | 46.77% | Wells Fargo | $10 → $15 | Upgrades | Equal-Weight → Overweight |
| 02/24/2023 | 17.42% | Citigroup | $10 → $12 | Maintains | Buy |
| 02/23/2023 | 95.69% | Canaccord Genuity | $18 → $20 | Maintains | Buy |
| 02/23/2023 | 7.63% | Morgan Stanley | $9.5 → $11 | Maintains | Equal-Weight |
| 01/06/2023 | -7.05% | Morgan Stanley | $14 → $9.5 | Maintains | Equal-Weight |
| 01/03/2023 | -21.72% | B of A Securities | → $8 | Downgrades | Neutral → Underperform |
| 12/12/2022 | -41.29% | Wells Fargo | $13.5 → $6 | Maintains | Equal-Weight |
| 12/12/2022 | -2.15% | Citigroup | $14 → $10 | Upgrades | Neutral → Buy |
| 11/07/2022 | 36.99% | Morgan Stanley | $19 → $14 | Maintains | Equal-Weight |
| 11/04/2022 | 27.2% | Piper Sandler | $25 → $13 | Maintains | Overweight |
| 10/11/2022 | 85.91% | Morgan Stanley | $21 → $19 | Maintains | Equal-Weight |
| 08/04/2022 | 105.48% | Morgan Stanley | $19 → $21 | Maintains | Equal-Weight |
| 08/03/2022 | 144.62% | Piper Sandler | $37 → $25 | Maintains | Overweight |
| 07/18/2022 | 95.69% | Stifel | $32 → $20 | Maintains | Buy |
| 07/15/2022 | 85.91% | Morgan Stanley | $30 → $19 | Maintains | Equal-Weight |
| 07/11/2022 | 85.91% | Citigroup | $23 → $19 | Downgrades | Buy → Neutral |
| 05/17/2022 | 125.05% | Citigroup | $32 → $23 | Maintains | Buy |
| 02/25/2022 | 193.54% | Morgan Stanley | $37 → $30 | Maintains | Equal-Weight |
| 02/24/2022 | 164.19% | Wells Fargo | $55 → $27 | Maintains | Equal-Weight |
| 01/07/2022 | 262.04% | Morgan Stanley | $48 → $37 | Maintains | Equal-Weight |
| 12/08/2021 | 340.31% | Piper Sandler | → $45 | Upgrades | Neutral → Overweight |
| 11/03/2021 | 438.16% | Wells Fargo | $56 → $55 | Maintains | Equal-Weight |
| 08/04/2021 | 418.59% | Canaccord Genuity | $65 → $53 | Maintains | Buy |
| 04/01/2021 | 487.08% | Citigroup | → $60 | Initiates Coverage On | → Buy |
| 03/25/2021 | 389.24% | Piper Sandler | → $50 | Initiates Coverage On | → Neutral |
| 03/10/2021 | 604.5% | B of A Securities | → $72 | Upgrades | Neutral → Buy |
| 03/03/2021 | 536.01% | Canaccord Genuity | $49 → $65 | Maintains | Buy |
| 03/03/2021 | 418.59% | Morgan Stanley | $52 → $53 | Maintains | Equal-Weight |
| 12/15/2020 | 408.81% | Morgan Stanley | $46 → $52 | Maintains | Equal-Weight |
| 11/11/2020 | 350.1% | Morgan Stanley | $44 → $46 | Maintains | Equal-Weight |
| 10/26/2020 | 389.24% | B of A Securities | → $50 | Initiates Coverage On | → Buy |
| 10/26/2020 | 379.45% | Canaccord Genuity | → $49 | Initiates Coverage On | → Buy |
| 10/26/2020 | 389.24% | Stifel | → $50 | Initiates Coverage On | → Buy |
| 10/26/2020 | 330.53% | Morgan Stanley | → $44 | Initiates Coverage On | → Equal-Weight |
| 10/26/2020 | 350.1% | Wells Fargo | → $46 | Initiates Coverage On | → Equal-Weight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/05/2023 | 76.13% | 克雷格-哈勒姆 | →$18 | 開始承保 | →購買 |
| 08/03/2023 | 66.34% | 派珀·桑德勒 | $15→$17 | 維護 | 超重 |
| 07/11/2023 | 56.56% | 花旗集團 | $14→$16 | 維護 | 買 |
| 05/03/2023 | 36.99% | 花旗集團 | $13→$14 | 維護 | 買 |
| 05/03/2023 | 46.77% | 派珀·桑德勒 | $13→$15 | 維護 | 超重 |
| 05/03/2023 | 36.99% | 摩根士丹利 | $11→$14 | 維護 | 等重 |
| 04/03/2023 | 27.2% | 花旗集團 | $12→$13 | 維護 | 買 |
| 02/27/2023 | 46.77% | 富國銀行 | $10→$15 | 升級 | 等重→超重 |
| 02/24/2023 | 17.42% | 花旗集團 | $10→$12 | 維護 | 買 |
| 02/23/2023 | 95.69% | 卡納科特·格納奇 | $18→$20 | 維護 | 買 |
| 02/23/2023 | 7.63% | 摩根士丹利 | $9.5→$11 | 維護 | 等重 |
| 01/06/2023 | -7.05% | 摩根士丹利 | $14→$9.5 | 維護 | 等重 |
| 01/03/2023 | -21.72% | B of A證券 | →$8 | 評級下調 | 中性→表現不佳 |
| 2022年12月12日 | -41.29% | 富國銀行 | $13.5→$6 | 維護 | 等重 |
| 2022年12月12日 | -2.15% | 花旗集團 | $14→$10 | 升級 | 中性→購買 |
| 11/07/2022 | 36.99% | 摩根士丹利 | $19→$14 | 維護 | 等重 |
| 11/04/2022 | 27.2% | 派珀·桑德勒 | $25→$13 | 維護 | 超重 |
| 2022年10月11日 | 85.91% | 摩根士丹利 | $21→$19 | 維護 | 等重 |
| 08/04/2022 | 105.48% | 摩根士丹利 | $19→$21 | 維護 | 等重 |
| 08/03/2022 | 144.62% | 派珀·桑德勒 | $37→$25 | 維護 | 超重 |
| 07/18/2022 | 95.69% | Stifel | $32→$20 | 維護 | 買 |
| 07/15/2022 | 85.91% | 摩根士丹利 | $30→$19 | 維護 | 等重 |
| 07/11/2022 | 85.91% | 花旗集團 | $23→$19 | 評級下調 | 購買→中性 |
| 2022/05/17 | 125.05% | 花旗集團 | $32→$23 | 維護 | 買 |
| 02/25/2022 | 193.54% | 摩根士丹利 | $37→$30 | 維護 | 等重 |
| 02/24/2022 | 164.19% | 富國銀行 | $55→$27 | 維護 | 等重 |
| 01/07/2022 | 262.04% | 摩根士丹利 | $48→$37 | 維護 | 等重 |
| 12/08/2021 | 340.31% | 派珀·桑德勒 | →$45 | 升級 | 中性→超重 |
| 11/03/2021 | 438.16% | 富國銀行 | $56→$55 | 維護 | 等重 |
| 08/04/2021 | 418.59% | 卡納科特·格納奇 | $65→$53 | 維護 | 買 |
| 04/01/2021 | 487.08% | 花旗集團 | →$60 | 開始承保 | →購買 |
| 03/25/2021 | 389.24% | 派珀·桑德勒 | →$50 | 開始承保 | →中性 |
| 03/10/2021 | 604.5% | B of A證券 | →$72 | 升級 | 中性→購買 |
| 03/03/2021 | 536.01% | 卡納科特·格納奇 | $49→$65 | 維護 | 買 |
| 03/03/2021 | 418.59% | 摩根士丹利 | $52→$53 | 維護 | 等重 |
| 12/15/2020 | 408.81% | 摩根士丹利 | $46→$52 | 維護 | 等重 |
| 11/11/2020 | 350.1% | 摩根士丹利 | $44→$46 | 維護 | 等重 |
| 10/26/2020 | 389.24% | B of A證券 | →$50 | 開始承保 | →購買 |
| 10/26/2020 | 379.45% | 卡納科特·格納奇 | →$49 | 開始承保 | →購買 |
| 10/26/2020 | 389.24% | Stifel | →$50 | 開始承保 | →購買 |
| 10/26/2020 | 330.53% | 摩根士丹利 | →$44 | 開始承保 | →等重 |
| 10/26/2020 | 350.1% | 富國銀行 | →$46 | 開始承保 | →等重 |
What is the target price for Pulmonx (LUNG)?
Pulmonx(肺)的目標價格是多少？
The latest price target for Pulmonx (NASDAQ: LUNG) was reported by Craig-Hallum on September 5, 2023. The analyst firm set a price target for $18.00 expecting LUNG to rise to within 12 months (a possible 76.13% upside). 18 analyst firms have reported ratings in the last year.
Craig-Hallum於2023年9月5日報道了Pulmonx(納斯達克：LONG)的最新目標價。這家分析公司將目標價定為18.00美元，預計肺臟將在12個月內上漲(可能上漲76.13%)。去年有18家分析公司公佈了評級。
What is the most recent analyst rating for Pulmonx (LUNG)?
分析師對Pulmonx(肺)的最新評級是多少？
The latest analyst rating for Pulmonx (NASDAQ: LUNG) was provided by Craig-Hallum, and Pulmonx initiated their buy rating.
Craig-Hallum提供了對Pulmonx(納斯達克代碼：LONG)的最新分析師評級，Pulmonx啟動了他們的買入評級。
When is the next analyst rating going to be posted or updated for Pulmonx (LUNG)?
下一次分析師對Pulmonx(肺)的評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pulmonx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pulmonx was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Pulmonx的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Pulmonx的上一次評級是在2023年9月5日提交的，所以你應該預計下一次評級將在2024年9月5日左右的某個時候公佈。
Is the Analyst Rating Pulmonx (LUNG) correct?
分析師對肺臟(肺)的評級正確嗎？
While ratings are subjective and will change, the latest Pulmonx (LUNG) rating was a initiated with a price target of $0.00 to $18.00. The current price Pulmonx (LUNG) is trading at is $10.22, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的肺(肺)評級是以0.00美元至18.00美元的目標價啟動的。目前Pulmonx(肺)的交易價格為10.22美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。